Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Novartis
Remibrutinib is an oral small-molecule kinase inhibitor that blocks Bruton's tyrosine kinase (BTK), along with the related kinases TEC and BMX. It inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators driven by pathogenic IgE or IgG.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 6, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05156281 | Phase 3 | Relapsing Multiple Sclerosis | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Papulopustular RosaceaRelapsing Multiple Sclerosis
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →